AVBP News
Archived Headlines
- Cancer biotech ArriVent BioPharma sets terms for $150 million IPO 01/22/24
- US IPO Week Ahead: January IPO market gets more large deals, led by health services firm BrightSpring 01/19/24
- Large filers bolster strong outlook for the 2024 IPO market 01/11/24
- US IPO Weekly Recap: 2024 IPO market starts off with two billion-dollar additions to the pipeline 01/05/24
- Cancer biotech ArriVent Biopharma files for a $100 million IPO 01/05/24
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
Renaissance Capital's January IPO Market Update
Eleven IPOs raised a combined $3.8 billion in January, the busiest month for both $100+ million and $1+ billion IPOs since late 2021. Six offerings raised $100 million or more, led by two billion-dollar deals: sports gear maker Amer Sports (AS) and...read more
US IPO Weekly Recap: Biotech CG Oncology pops 96% in a 7 IPO week
Seven IPOs priced this past week, led by three that raised $100+ million.After upwardly revising the terms earlier in the week, CG Oncology (CGON) further upsized the offering and priced above the range to raise $380 million at a $1.3 billion market cap. Its...read more
Cancer biotech ArriVent BioPharma prices upsized IPO at $18 midpoint
ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for EGFR-mutated lung cancer, raised $175 million by offering 9.7 million shares at $18, within the range of $17 to $19. The company offered 1.4 million more shares than anticipated....read more